Table 1. Baseline characteristics of the study cohort stratified by pathologic complete response (n = 176).
| Characteristics | Total patients | Non-pCR | pCR | p-value | |
|---|---|---|---|---|---|
| No. of patients | 176 (100) | 69 (39.2) | 107 (60.8) | ||
| Age at diagnosis | 50 (25–74) | 49 (25–74) | 51 (26–73) | 0.117 | |
| < 50 | 84 (47.7) | 38 (45.2) | 46 (54.8) | ||
| ≥ 50 | 92 (43.2) | 31 (33.7) | 61 (66.3) | ||
| Menopausal state | 0.384 | ||||
| Premenopausal | 100 (56.8) | 42 (42.0) | 58 (58.0) | ||
| Postmenopausal | 76 (43.2) | 27 (35.5) | 49 (64.5) | ||
| Clinical stage at diagnosed (AJCC 7th) | 0.260 | ||||
| Stage II | 96 (54.5) | 34 (35.8) | 62 (64.6) | ||
| Stage III | 80 (45.5) | 35 (43.8) | 45 (56.3) | ||
| Clinical nodal status | 0.052 | ||||
| LN negative | 53 (30.1) | 15 (28.3) | 38 (71.7) | ||
| LN positive | 123 (69.9) | 54 (43.9) | 69 (56.1) | ||
| HR status | 0.001 | ||||
| HR (−) | 83 (47.2) | 22 (26.5) | 61 (73.5) | ||
| HR (+) | 93 (52.8) | 47 (50.5) | 46 (49.5) | ||
| Ki-67 | 0.655 | ||||
| Low (< 20%) | 4 (2.3) | 2 (50.0) | 2 (50.0) | ||
| High (≥ 20%) | 172 (97.7) | 67 (39.0) | 105 (61.0) | ||
| Histologic grade | 0.475 | ||||
| I, II | 130 (73.9) | 53 (40.8) | 77 (59.2) | ||
| III | 46 (26.1) | 16 (34.8) | 30 (65.2) | ||
| TILs | 15.0 (0–75) | 5.0 (0–75) | 15.0 (0–75) | 0.035 | |
| < 20% | 125 (71.0) | 56 (44.8) | 69 (55.2) | ||
| ≥ 20% | 48 (27.3) | 13 (27.1) | 35 (72.9) | ||
| Unknown | 3 (1.7) | 0 | 3 (100) | ||
Values are presented as median (range) or number (%).
pCR = pathological complete response; AJCC = American Joint Committee on Cancer; LN = lymph node; HR = hormone receptor; TIL = tumor-infiltrating lymphocyte.